Drug Delivery Systems for Tuberculosis Prevention and Treatment: Advances in Pharmaceutical Technology
Autor AJ Hickeyen Limba Engleză Hardback – 10 noi 2016
Preț: 752.63 lei
Preț vechi: 1100.93 lei
-32% Nou
Puncte Express: 1129
Preț estimativ în valută:
144.06€ • 151.23$ • 119.00£
144.06€ • 151.23$ • 119.00£
Carte indisponibilă temporar
Doresc să fiu notificat când acest titlu va fi disponibil:
Se trimite...
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781118943175
ISBN-10: 1118943171
Pagini: 456
Dimensiuni: 173 x 251 x 26 mm
Greutate: 0.84 kg
Editura: Wiley
Seria Advances in Pharmaceutical Technology
Locul publicării:Chichester, United Kingdom
ISBN-10: 1118943171
Pagini: 456
Dimensiuni: 173 x 251 x 26 mm
Greutate: 0.84 kg
Editura: Wiley
Seria Advances in Pharmaceutical Technology
Locul publicării:Chichester, United Kingdom
Public țintă
Pharmaceutical scientists, technologists and engineers, with an interest in lung targeting and aerosols. Researchers in industry and academia working on TB treatment and prevention (including microbiologists, immunologist and molecular biologists). Pulmonary and infectious disease clinicians.
Cuprins
Notă biografică
Anthony J. Hickey, Distinguished Fellow (appointed June 2012), is a Program Director in Inhaled Therapeutics in the Center for Aerosol and Nanomaterials Engineering at the Research Triangle Institute, North Carolina, USA. Dr Hickey has more than 30 years of academic and research experience in pulmonary biology, aerosol physics, powder dynamics, pharmacokinetics and drug disposition, formulation design, and device development. Since joining RTI in 2011, he has conducted research related to pulmonary drug and vaccine delivery for tuberculosis treatment and therapy. Additionally, Dr. Hickey is an adjunct professor of biomedical engineering at the University of North Carolina at Chapel Hill School of Medicine, emeritus professor of molecular pharmaceutics at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy, and founder and president of Cirrus Pharmaceuticals, Inc.